SCHEMBL570256

SCHEMBL570256

c1ccc(COc2ccc(-c3cc[nH]n3)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MEN1 O00255 1/20 0.56
NPC1 O15118 1/20 0.56
POLB P06746 1/20 0.56
KMT2A Q03164 1/20 0.56
XDH P47989 1/20 0.53
ENPP3 O14638 1/20 0.52
ENPP1 P22413 1/20 0.52
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
PTGS1 P23219 1/20 0.51
SLC6A2 P23975 1/20 0.51
CYP2C19 P33261 1/20 0.51
PTGS2 P35354 1/20 0.51
SLC6A3 Q01959 1/20 0.51
HIF1A Q16665 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
GSTP1 P09211 1/20 0.51
IKBKE Q14164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924350 0.83 MAOB (0.50) MAOBMAOAL3MBTL1BCHENR4A2
SCHEMBL14638496 0.81 MAPK1 (0.45) MEN1KMT2AGAAMCL1MAPT
SCHEMBL197017 0.78 LMNA (0.72) RAB9ASMN1; SMN2MEN1NPC1POLB
SCHEMBL28866549 0.78 MAOB (0.49) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL6350969 0.78 L3MBTL1 (0.63) SMN1; SMN2LMNAMAPTL3MBTL1
SCHEMBL3364770 0.78 NPC1 (0.50) RAB9ANPC1XDHGSTP1MCL1
SCHEMBL6256087 0.77 SMN1; SMN2 (0.49) RAB9ASMN1; SMN2MEN1NPC1POLB
SCHEMBL12473775 0.77 MAOB (0.48) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL27743534 0.77 CYP1A2 (0.61) RAB9ASMN1; SMN2MEN1NPC1POLB
SCHEMBL23483029 0.77 LMNA (0.69) RAB9ASMN1; SMN2MEN1NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103476252-B Pyrazolyl guanidine F1F 0-ATPase inhibitors and therapeutic uses thereof 莱斯拉公司 2017-02-22 CN disclosed
EP-2601192-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2013-06-12 EP disclosed
WO-2012018909-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-09 WO disclosed